INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80
VIB0551.P3.S2
Phase 3 small_molecule active
Quick answer
INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80 for Immunoglobulin G4-related disease (IgG4-RD) is a Phase 3 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Elan Pharma International
- Indication
- Immunoglobulin G4-related disease (IgG4-RD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active